title: Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
abstract: Lung cancer still remains associated with a high mortality rate and more efficacious therapies are needed in order to improve the disease outcome. Nivolumab is a monoclonal antibody which blocks the programmed death-1 receptor which is currently evaluated in phase III clinical trials in advanced lung cancer. Here, we evaluate the results of a phase III study in which nivolumab efficacy and safety were compared to those of docetaxel. Nivolumab was able to improve survival and progression-free survival and exhibited a very good safety profile. Further clinical data are needed in order to better position this therapy among the existing methods. The promising results support the use of this therapy as a stand-alone approach.
authors.affiliation: a Marius Nasta Institute , Bucuresti , Romania.|b Faculty of Medicine, University of Medicine Oradea , Bucuresti , Romania.
authors.forename: Ruxandra
authors.initials: R
authors.lastname: Ulmeanu
authors.affiliation: c Department of Interdisciplinarity and Preventive Medicine , University of Medicine and Pharmacy Gr T Popa , Iasi , Romania.
authors.forename: Ileana
authors.initials: I
authors.lastname: Antohe
authors.affiliation: d Immunology Laboratory, Sf Spiridon University Hospital , Iasi , Romania.
authors.forename: Ecaterina
authors.initials: E
authors.lastname: Anisie
authors.affiliation: c Department of Interdisciplinarity and Preventive Medicine , University of Medicine and Pharmacy Gr T Popa , Iasi , Romania.
authors.forename: Sabina
authors.initials: S
authors.lastname: Antoniu
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077594:Nivolumab; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D000077594:Nivolumab
keywords: Nivolumab; PD-1; lung cancer; monoclonal antibody